![Pete Shagory](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pete Shagory
Corporate Officer/Principal at
CONMED CORPORATION
Net worth: 139 123 $ as of 2026-05-30
Profile
Pete K.
Shagory is Executive VP-Strategy & Corporate Development at CONMED Corp.
since 2015.
Former roles include Director positions at CoAxia, Inc., Accuri Cytometers, Inc., Arbor Surgical Technologies, Inc., Caden Biosciences, Inc., NimbleGen Systems, Inc., Bioforward, Inc., Core Essence Orthopaedics, Inc., and Molecular Imaging, Inc. Manager roles at Banc One Capital Markets, Inc. and J.P.
Morgan & Co., Inc. (Old).
Partner at Robert W.
Baird & Co., Inc. from 2004 to 2013.
Portfolio Manager at Vector Asset Management, Inc. Education includes undergraduate studies at Miami University and an MBA from Tuck School of Business at Dartmouth.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CONMED CORPORATION 0.01% | 2026-03-23 | 3,897 ( 0.01% ) | 139 123 $ | 2026-05-30 |
Pete Shagory active positions
| Companies | Position | Start |
|---|---|---|
| CONMED CORPORATION | Corporate Officer/Principal | 2015-05-10 |
Former positions of Pete Shagory
| Companies | Position | End |
|---|---|---|
Robert W. Baird & Co., Inc. /Venture Partners/
 Robert W. Baird & Co., Inc. /Venture Partners/ Investment ManagersFinance Baird Capital invests in middle market companies located in the United States with annual revenues of USD 5 - 25 million. The firm focuses on B2B technology & services sector. It participates in early to growth stage transactions with an investment size ranging from USD 15 to 25 million. It acquires majority and minority interest and also takes a seat on the board of directors. | Private Equity Investor | 2013-05-31 |
Caden Biosciences, Inc.
 Caden Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops assays for G-protein coupled receptors | Director/Board Member | 2009-09-09 |
Bioforward, Inc.
 Bioforward, Inc. Investment ManagersFinance Alternative investment manager | Corporate Officer/Principal | 2008-12-30 |
NimbleGen Systems, Inc.
 NimbleGen Systems, Inc. BiotechnologyHealth Technology Develops micro-arrays used in bio-technology | Director/Board Member | 2008-12-29 |
Vector Asset Management, Inc.
 Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | Private Equity Investor | 2003-12-29 |
Training of Pete Shagory
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
40
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
CONMED Corp.
 CONMED Corp. Medical SpecialtiesHealth Technology Operates as a medical technology company, which provides surgical devices and equipment for minimally invasive procedures and monitoring | Health Technology |
CoAxia, Inc.
 CoAxia, Inc. Medical/Nursing ServicesHealth Services Develops & markets technologies to reduce neurologic damage | Health Services |
Accuri Cytometers, Inc.
 Accuri Cytometers, Inc. Medical SpecialtiesHealth Technology Develops and manufactures personal flow cytometers | Health Technology |
Arbor Surgical Technologies, Inc.
 Arbor Surgical Technologies, Inc. Medical SpecialtiesHealth Technology Develops cardiovascular medical devices | Health Technology |
Caden Biosciences, Inc.
Caden Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops assays for G-protein coupled receptors | Health Technology |
Banc One Capital Markets, Inc.
 Banc One Capital Markets, Inc. Investment Banks/BrokersFinance Provides security brokerage services | Finance |
J.P. Morgan & Co., Inc. (Old)
 J.P. Morgan & Co., Inc. (Old) Regional BanksFinance Provides commercial banking and investment advisory services | Finance |
NimbleGen Systems, Inc.
NimbleGen Systems, Inc. BiotechnologyHealth Technology Develops micro-arrays used in bio-technology | Health Technology |
Miami University
 Miami University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert W. Baird & Co., Inc. /Venture Partners/
Robert W. Baird & Co., Inc. /Venture Partners/ Investment ManagersFinance Baird Capital invests in middle market companies located in the United States with annual revenues of USD 5 - 25 million. The firm focuses on B2B technology & services sector. It participates in early to growth stage transactions with an investment size ranging from USD 15 to 25 million. It acquires majority and minority interest and also takes a seat on the board of directors. | Finance |
Bioforward, Inc.
Bioforward, Inc. Investment ManagersFinance Alternative investment manager | Finance |
Vector Asset Management, Inc.
Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | Finance |
Core Essence Orthopaedics, Inc.
 Core Essence Orthopaedics, Inc. Medical SpecialtiesHealth Technology Develops and manufactures minimally invasive soft tissue and arthroscopic musculoskeletal surgical solutions | Health Technology |
Molecular Imaging, Inc.
 Molecular Imaging, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research services supported by extensive in vivo imaging capabilities | Commercial Services |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Pete Shagory
